share_log

Jin Medical International | 6-K: Report of foreign private issuer (related to financial reporting)

Jin Medical International | 6-K: Report of foreign private issuer (related to financial reporting)

中進醫療 | 6-K:外國發行人報告(業績相關)
美股SEC公告 ·  07/26 16:14

Moomoo AI 已提取核心訊息

Jin Medical International Ltd. (Jin Medical), a Cayman Islands exempted company, has furnished its unaudited condensed consolidated financial statements for the six months ended March 31, 2024, as part of its current report on Form 6-K. The report, filed with the SEC for July 2024, includes detailed financial performance indicators such as revenue, gross profit and margin, operating expenses, and operating income. Jin Medical, through its China-based VIE, Changzhou Zhongjin, and subsidiaries, primarily designs and manufactures wheelchairs and living aids for the disabled, elderly, and those recovering from injuries, with a focus on wheelchairs. The majority of its products are sold to dealers in Japan and China, with a smaller number distributed to other regions. The company's revenue is primarily derived...Show More
Jin Medical International Ltd. (Jin Medical), a Cayman Islands exempted company, has furnished its unaudited condensed consolidated financial statements for the six months ended March 31, 2024, as part of its current report on Form 6-K. The report, filed with the SEC for July 2024, includes detailed financial performance indicators such as revenue, gross profit and margin, operating expenses, and operating income. Jin Medical, through its China-based VIE, Changzhou Zhongjin, and subsidiaries, primarily designs and manufactures wheelchairs and living aids for the disabled, elderly, and those recovering from injuries, with a focus on wheelchairs. The majority of its products are sold to dealers in Japan and China, with a smaller number distributed to other regions. The company's revenue is primarily derived from wheelchair sales and components, and living aids products. Key financial results for the six months ended March 31, 2024, show a 3.0% increase in revenue and a 1.6% increase in net income attributable to Jin Medical International Ltd. compared to the same period in 2023. Gross profit increased by 5.8%, while operating expenses rose by 42.5%. The company also reported a 30.6% decrease in income from operations and a 51.4% increase in income tax provision. Jin Medical's shares began trading on the Nasdaq Capital Market under the symbol 'ZJYL' on March 28, 2023, following an initial public offering. The company's cash and short-term investments have increased since September 30, 2023, and it expects to meet its working capital needs for the foreseeable future through current cash, operating activities, bank borrowings, and IPO proceeds.
美國證券交易委員會(SEC)規定,開曼群島的豪潔醫療國際有限公司(Jin Medical International Ltd.)已發佈截至2024年3月31日的未經審計的簡明合併財務報表,作爲其第6-k表格的重要組成部分。該報告已在2024年7月向SEC提交,其中包括營業收入、毛利潤及利潤率、營業費用和營業收入等詳細的財務業績指標。豪潔醫療主要通過其中國境內的可變利益實體常州中進和附屬公司,以輪椅和生活輔助用品爲主要產品,爲殘疾人、老年人及康復中的人提供服務,其中輪椅是其重點產品。其產品主要銷往經銷商,包括日本和中國,少部分產品分佈在其他地區。公司的營業收入主要來自輪椅及其元件,以及生活輔助用...展開全部
美國證券交易委員會(SEC)規定,開曼群島的豪潔醫療國際有限公司(Jin Medical International Ltd.)已發佈截至2024年3月31日的未經審計的簡明合併財務報表,作爲其第6-k表格的重要組成部分。該報告已在2024年7月向SEC提交,其中包括營業收入、毛利潤及利潤率、營業費用和營業收入等詳細的財務業績指標。豪潔醫療主要通過其中國境內的可變利益實體常州中進和附屬公司,以輪椅和生活輔助用品爲主要產品,爲殘疾人、老年人及康復中的人提供服務,其中輪椅是其重點產品。其產品主要銷往經銷商,包括日本和中國,少部分產品分佈在其他地區。公司的營業收入主要來自輪椅及其元件,以及生活輔助用品銷售。2024年3月31日的六個月關鍵財務業績數據顯示,與2023年同期相比,營業收入增長3.0%,歸屬於豪潔醫療國際有限公司的淨利潤增長1.6%。毛利潤增長了5.8%,而營業費用上升了42.5%。公司報告中還宣佈,營業收入下降了30.6%,所得稅費用增加了51.4%。豪潔醫療的股票自2023年3月28日開始在納斯達克資本市場上交易,其股票代碼爲“ZJYL”,並進行了首次公開募股。該公司現金及短期投資已自2023年9月30日以來增加,並預計通過現有資金、營業活動、銀行借款和首次公開募股所得款項滿足未來的營運資金需求。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息